Recent trends in brand-name and generic drug competition

Figures & data

Figure 1. Average market exclusivity period by year of first generic entry: new molecular entities.

Table 1. Average market exclusivity period by year of first generic entry.

Year of first generic entry	New molecules with sales greater than $100 million	All new molecules
	Mean, in years (SD)	Mean, in years (SD)
1995–1996	12.7 (7.5)	13.5 (6.9)
1997–1998	13.5 (7.0)	13.7 (5.5)
1999–2000	10.5 (3.2)	13.5 (6.4)
2001–2002	12.6 (3.6)	13.6 (4.5)
2003–2004	11.1 (3.6)	13.5 (6.2)
2005–2006	12.1 (3.8)	13.2 (5.3)
2007–2008	11.5 (2.9)	12.2 (3.6)
2009–2010	13.4 (2.3)	13.5 (3.6)
2011–2012	12.6 (2.7)	12.9 (3.2)

Source: IMS Health National Sales Perspectives data on all new drugs with initial generic entry in the period 1995 through September 2012.

Notes: New molecules with sales greater than $100 million based on sales in the year prior to generic entry and inflation-adjusted to 2008 dollars using the Consumer Price Index for All Urban Consumers.

Figure 2. Average number of generic entrants within 1 year of first generic entry: new molecular entities.

Figure 3. Paragraph IV filing frequency and timing (3-year moving average).

Figure 4. Average monthly brand share of standard units of the molecule/form following first generic entry.